tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

ARVN Stock Latest News

Arvinas upgraded to Buy from Neutral at Citi
The FlyArvinas upgraded to Buy from Neutral at Citi
10d ago
ARVN
Arvinas price target raised to $18 from $16 at Barclays
PremiumThe Fly
Arvinas price target raised to $18 from $16 at Barclays
30d ago
ARVN
Arvinas Reveals Promising Preclinical Data for ARV-393
PremiumCompany Announcements
Arvinas Reveals Promising Preclinical Data for ARV-393
1M ago
8K
ARVN
Arvinas announces preclinical data for ARV-393
PremiumThe Fly
Arvinas announces preclinical data for ARV-393
1M ago
ARVN
Arvinas price target raised to $15 from $14 at Stephens
PremiumThe Fly
Arvinas price target raised to $15 from $14 at Stephens
2M ago
ARVN
Arvinas Holding Company: Balancing Potential and Uncertainty with a Hold Rating
PremiumRatingsArvinas Holding Company: Balancing Potential and Uncertainty with a Hold Rating
2M ago
ARVN
Promising Pipeline Developments and Strategic Shift Justify Buy Rating for Arvinas Holding Company
Premium
Ratings
Promising Pipeline Developments and Strategic Shift Justify Buy Rating for Arvinas Holding Company
2M ago
ARVN
Arvinas Reports Q3 2025 Earnings and Strategic Progress
Premium
Company Announcements
Arvinas Reports Q3 2025 Earnings and Strategic Progress
2M ago
ARVN
Arvinas Earnings Call: Promising Pipeline Amid Revenue Challenges
PremiumCompany Announcements
Arvinas Earnings Call: Promising Pipeline Amid Revenue Challenges
2M ago
ARVN
Cautious Hold Rating for Arvinas Holding: Balancing Promising Pipeline with Clinical Uncertainties
PremiumRatings
Cautious Hold Rating for Arvinas Holding: Balancing Promising Pipeline with Clinical Uncertainties
2M ago
ARVN
Arvinas sees cash runway into 2H28
PremiumThe Fly
Arvinas sees cash runway into 2H28
2M ago
ARVN
Arvinas reports Q3 EPS (48c), consensus (74c)
PremiumThe Fly
Arvinas reports Q3 EPS (48c), consensus (74c)
2M ago
ARVN
Arvinas price target raised to $14 from $10 at BTIG
PremiumThe FlyArvinas price target raised to $14 from $10 at BTIG
3M ago
ARVN
Arvinas Advances in KRAS G12D Mutation Treatment with ARV-806 Study
Premium
Company Announcements
Arvinas Advances in KRAS G12D Mutation Treatment with ARV-806 Study
3M ago
ARVN
Arvinas’ ARV-393: A New Hope in Non-Hodgkin’s Lymphoma Treatment?
Premium
Company Announcements
Arvinas’ ARV-393: A New Hope in Non-Hodgkin’s Lymphoma Treatment?
3M ago
ARVN
Arvinas Unveils Promising Preclinical Data for ARV-806
PremiumCompany Announcements
Arvinas Unveils Promising Preclinical Data for ARV-806
3M ago
8K
ARVN
Arvinas presents preclinical data for ARV-806
PremiumThe Fly
Arvinas presents preclinical data for ARV-806
3M ago
ARVN
Arvinas Reports Promising Phase 3 Trial Results
PremiumCompany Announcements
Arvinas Reports Promising Phase 3 Trial Results
3M ago
8K
ARVN
Arvinas announces new patient-reported outcomes data from VERITAC-2 trial
PremiumThe Fly
Arvinas announces new patient-reported outcomes data from VERITAC-2 trial
3M ago
PFE
ARVN
Arvinas downgraded to Sell from Neutral at Goldman Sachs
PremiumThe FlyArvinas downgraded to Sell from Neutral at Goldman Sachs
3M ago
ARVN
Cautious Outlook for Arvinas Holding: Hold Rating Amid Uncertain Commercial Strategy for Vepdegestrant
Premium
Ratings
Cautious Outlook for Arvinas Holding: Hold Rating Amid Uncertain Commercial Strategy for Vepdegestrant
3M ago
ARVN
Arvinas price target raised to $16 from $14 at Piper Sandler
Premium
The Fly
Arvinas price target raised to $16 from $14 at Piper Sandler
3M ago
PFE
ARVN

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >